EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

Guangyi Xu iD, Yu An, Yage Du, Zhaoming Cao, Jie Zheng, Jingya Wang, Tingyi Li, Xingen Lei, Yanhui Lu iD

iMetaOmics · 2025-09 · 2 (3)

DOI: 10.1002/imo2.70020 ↗

At a glance

Übersichtsarbeit in iMetaOmics, published online on 2025-05-11. Written by Guangyi Xu and 8 co-authors. Institution: School of Nursing Peking University Beijing China. Cited 6 times so far (Crossref); 350 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Epidemiological studies suggest a link between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), possibly due to gut microbiota dysbiosis, although the exact mechanisms are unclear. This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in T2DM and AD, proposing a framework for dual therapeutic targeting. This narrative review provides an in‐depth examination of the roles and mechanisms of gut microbiota and their metabolites in the context of T2DM and AD. This study indicates that gut microbiota dysbiosis significantly impacts the pathogenesis and progression of both diseases by modulating metabolic pathways, immune functions, and inflammatory responses. Key bacteria, such as Akkermansia muciniphila (which releases outer membrane vesicles), Lactobacillus , and Bifidobacterium , as well as their metabolites like short‐chain fatty acids (SCFAs), bile acids (BAs), lipopolysaccharide (LPS), vitamins, and Trimethylamine N‐oxide (TMAO) regulate T2DM and AD through complex mechanisms. Multiple signaling pathways, including G‐protein coupled receptor 41/43 (GPR41/43), phosphoinositide 3‐kinase (PI3K)/protein kinase B (Akt), Toll‐like receptor 4 (TLR4)/nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), and endoplasmic reticulum (ER) stress‐mediated pathways, are also involved. These findings offer insights into the pathogenesis and potential targeted therapies for T2DM and AD.

Subjects

Author keywords

Alzheimer's diseasegut microbiotametabolitestype 2 diabetes mellitus

Authors and institutions

  • School of Nursing Peking University Beijing China.
  • Medical Research Center Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University Beijing China.
  • Department of Biostatistics School of Public Health, Columbia University New York New York USA.
  • Department of Animal Science Cornell University Ithaca New York USA.

ORCID profiles: Guangyi Xu, Yanhui Lu

Cite

APA

Xu, G., An, Y., Du, Y., Cao, Z., Zheng, J., Wang, J., Li, T., Lei, X., & Lu, Y. (2025). Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease. iMetaOmics, 2(3). https://doi.org/10.1002/imo2.70020

Vancouver

Xu G, An Y, Du Y, Cao Z, Zheng J, Wang J, et al. Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease. iMetaOmics. 2025;2(3). doi:10.1002/imo2.70020

BibTeX
@article{Xu2025,
  author = {Xu, Guangyi and An, Yu and Du, Yage and Cao, Zhaoming and Zheng, Jie and Wang, Jingya and Li, Tingyi and Lei, Xingen and Lu, Yanhui},
  title = {Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease},
  journal = {iMetaOmics},
  year = {2025},
  volume = {2},
  number = {3},
  doi = {10.1002/imo2.70020}
}
Start for free →